{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:42:57Z","timestamp":1786203777623,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Doxorubicin-cyclophosphamide (AC) and docetaxel-cyclophosphamide (TC) are standard perioperative chemotherapy regimens for breast cancer. Febrile neutropenia (FN) is a common adverse event, and odontogenic infections may contribute to febrile episodes. This study was performed to investigate the incidence and impact of febrile episodes clinically associated with odontogenic infections during AC and TC chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 408 patients with breast cancer receiving 4 cycles of AC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009285) or TC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009123) between 2015 and 2020 were included in this single-center retrospective study. Patients recorded daily axillary temperatures and oral symptoms. Dental evaluations were performed when oral infection was suspected. Febrile episodes (\u2265\u200937.5\u00a0\u00b0C) were assessed, and their clinical association with odontogenic infections was determined based on dental records and the documented clinical course. Relative dose intensity (RDI) was calculated to assess chemotherapy delivery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 40.2% of patients experienced febrile episodes, and the frequency was higher in the TC group (48.8%) than the AC group (36.5%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.02). Febrile episodes associated with oral infections occurred in 9.1% of patients, of which 78.4% were clinically associated with odontogenic infections (7.1% of all patients). Most such episodes occurred during the first chemotherapy cycle (79.3%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). Chemotherapy RDI was reduced in three patients with febrile episodes clinically associated with odontogenic infection, but remained\u2009\u2265\u200985%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Febrile episodes clinically associated with odontogenic infections occurred in approximately 7%\u20138% of patients with breast cancer receiving perioperative AC or TC chemotherapy, predominantly during the first cycle. Odontogenic infections should be considered one possible source of febrile episodes during treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10977-4","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:50:08Z","timestamp":1783579808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and impact of odontogenic infection-related febrile episodes during perioperative doxorubicin-cyclophosphamide or docetaxel-cyclophosphamide chemotherapy for breast cancer"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-1474","authenticated-orcid":false,"given":"Yoshihiko","family":"Soga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8686-1818","authenticated-orcid":false,"given":"Kumiko","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6444-8043","authenticated-orcid":false,"given":"Hirotaka","family":"Kosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2984-6544","authenticated-orcid":false,"given":"Tomoko","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-5340","authenticated-orcid":false,"given":"Aiko","family":"Yoshitomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4683-3225","authenticated-orcid":false,"given":"Makoto","family":"Kajizono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2276-7217","authenticated-orcid":false,"given":"Takashi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7291-8854","authenticated-orcid":false,"given":"Yuta","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7879-423X","authenticated-orcid":false,"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3202-5512","authenticated-orcid":false,"given":"Tadahiko","family":"Shien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2989-2730","authenticated-orcid":false,"given":"Hiroyoshi","family":"Doihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"10977_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","volume":"96\u2013102","author":"N Wolmark","year":"2001","unstructured":"Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 96\u2013102:96. https:\/\/doi.org\/10.1093\/oxfordjournals.jncimonographs.a003469","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10977_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","volume":"27","author":"S Jones","year":"2009","unstructured":"Jones S, Holmes FA, O\u2019Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177\u20131183. https:\/\/doi.org\/10.1200\/JCO.2008.18.4028","journal-title":"J Clin Oncol"},{"key":"10977_CR3","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","volume":"24","author":"SE Jones","year":"2006","unstructured":"Jones SE, Savin MA, Holmes FA, O\u2019Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381\u20135387. https:\/\/doi.org\/10.1200\/JCO.2006.06.5391","journal-title":"J Clin Oncol"},{"key":"10977_CR4","unstructured":"National Comprehensive Cancer Network (2025) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) - Hematopoietic growth factors. Version 3.2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1493. Accessed 21 Jan 2026"},{"key":"10977_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215576","volume":"14","author":"Y Furuya","year":"2019","unstructured":"Furuya Y (2019) Early neutropenia on day 8 treated with adjuvant Docetaxel-based chemotherapy in early breast cancer patients: putative mechanisms within the neutrophil pool system. PLoS ONE 14:e0215576. https:\/\/doi.org\/10.1371\/journal.pone.0215576","journal-title":"PLoS ONE"},{"key":"10977_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Lago LD, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"key":"10977_CR7","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199\u20133212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"key":"10977_CR8","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1007\/s00520-019-04925-8","volume":"27","author":"J Zecha","year":"2019","unstructured":"Zecha J, Raber-Durlacher JE, Laheij A, Westermann AM, Epstein JB, de Lange J, Smeele LE (2019) The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy. Support Care Cancer 27:3667\u20133679. https:\/\/doi.org\/10.1007\/s00520-019-04925-8","journal-title":"Support Care Cancer"},{"key":"10977_CR9","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12282-023-01505-x","volume":"30","author":"M Terada","year":"2023","unstructured":"Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, Ishihara M, Yamanaka T, Ozaki Y, Hara F, Nakamura R, Hattori M, Miyashita M, Kondo N, Yoshinami T, Takada M, Matsumoto K, Narui K, Sasada S, Iwamoto T, Hosoda M, Takano Y, Oba T, Sakai H, Murakami A, Higuchi T, Tsuchida J, Tanabe Y, Shigechi T, Tokuda E, Harao M, Kashiwagi S, Mase J, Watanabe J, Nagai SE, Yamauchi C, Yamamoto Y, Iwata H, Saji S, Toyama T (2023) The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition. Breast Cancer (Auckl) 30:872\u2013884. https:\/\/doi.org\/10.1007\/s12282-023-01505-x","journal-title":"Breast Cancer (Auckl)"},{"key":"10977_CR10","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1086\/383054","volume":"39","author":"T Masaoka","year":"2004","unstructured":"Masaoka T (2004) Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 39:S49\u2013S52. https:\/\/doi.org\/10.1086\/383054","journal-title":"Clin Infect Dis"},{"key":"10977_CR11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jjco\/hyp050","volume":"39","author":"D Takabatake","year":"2009","unstructured":"Takabatake D, Taira N, Hara F, Sien T, Kiyoto S, Takashima S, Aogi K, Ohsumi S, Doihara H, Takashima S (2009) Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn J Clin Oncol 39:478\u2013483. https:\/\/doi.org\/10.1093\/jjco\/hyp050","journal-title":"Jpn J Clin Oncol"},{"key":"10977_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10549-017-4646-1","volume":"169","author":"L Zhang","year":"2018","unstructured":"Zhang L, Yu Q, Wu XC, Hsieh MC, Loch M, Chen VW, Fontham E, Ferguson T (2018) Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+\/PR+, HER2- vs. triple-negative. Breast Cancer Res Treat 169:175\u2013187. https:\/\/doi.org\/10.1007\/s10549-017-4646-1","journal-title":"Breast Cancer Res Treat"},{"key":"10977_CR13","unstructured":"Japanese Ministry of Health, Labour and Welfare (2023) Survey of dental diseases. https:\/\/www.e-stat.go.jp\/stat-search\/file-download?statInfId=000040118556&fileKind=0. Accessed 21 Jan 2026"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10977-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10977-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10977-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T14:55:52Z","timestamp":1786200952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10977-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10977"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10977-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8691511\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Ethics Committee approved this study (Ken 2004-035 and Ken 2509-056).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained by opt-out according to the Ethical Guidelines for Medical and Biological Research Involving Human Subjects of the Japanese Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare, and Ministry of Economy, Trade and Industry. All procedures were performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"747"}}